BEUDAMED
    FDA Adverse Event Malfunction Summary report: N

    VITROS CHEMISTRY PRODUCTS CREA SLIDES

    MDR report key: 24791868 · Received April 6, 2026

    Report

    Report Number
    1319809-2026-00035
    Event Type
    Malfunction
    Date Received
    April 6, 2026
    Date of Event
    March 2, 2026
    Report Date
    April 6, 2026
    Manufacturer
    ORTHO-CLINICAL DIAGNOSTICS, INC.
    Product Code
    JFY
    UDI-DI
    10758750002849
    Product Problem
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    US
    Reporter Occupation
    OTHER HEALTH CARE PROFESSIONAL
    Health Professional
    Yes

    Narratives

    Additional Manufacturer Narrative · 0

    THE INVESTIGATION DETERMINED THAT HIGHER THAN EXPECTED VITROS CREATININE (CREA) RESULTS WERE OBTAINED FROM MULTIPLE PATIENT SAMPLES WHEN TESTED ON TWO VITROS 5600 INTEGRATED SYSTEMS. THE RESULTS WERE HIGHER THAN EXPECTED WHEN COMPARED TO RESULTS OBTAINED FROM PROCESSING THE SAME PATIENT SAMPLES ON AN ALTERNATE (ROCHE) METHOD. THE ASSIGNABLE CAUSE OF THE EVENT WAS UNABLE TO BE DETERMINED. IT IS POSSIBLE THAT AN INTERFERENT WAS PRESENT IN THE AFFECTED PATIENT SAMPLES, ALTHOUGH THIS CANNOT BE CONFIRMED WITH THE INFORMATION PROVIDED. PER THE VITROS CREA INSTRUCTIONS FOR USE (IFU), LIMITATIONS OF THE PROCEDURE, KNOWN INTERFERENCES: CREATINE: "AT A CREATININE (SERUM AND PLASMA) CONCENTRATION OF 1.5 MG/DL, CREATINE GREATER THAN 8 MG/DL WILL BE FLAGGED WITH A DP (SUBSTRATE DEPLETION) CODE (BECAUSE HIGHLY ELEVATED CREATINE CONCENTRATIONS MAY CAUSE EXCESSIVE BACKGROUND DENSITY). AT A CREATININE CONCENTRATION OF 14 MG/DL, CREATINE GREATER THAN 1 MG/DL WILL BE FLAGGED WITH A DP CODE." THE VITROS 5600 INTEGRATED SYSTEMS DID NOT GENERATE VITROS CREA RESULTS WHEN THE PATIENT SAMPLE WAS TESTED UNDILUTED AND WITH THE 1:2 DILUTION DUE TO THE OCCURRENCE OF A "DP" SAMPLE CODE, WHICH INDICATES SUBSTRATE DEPLETION. THE MOST LIKELY CAUSE OF THE DP SAMPLE CODES IS AN INTERFERENT IN THE SAMPLE, SUCH A CREATINE, WHICH WOULD BE DILUTED OUT WITH THE SAMPLE DILUTION PRIOR TO REPEAT TESTING. PER THE VITROS FLAGS AND CODES ON REPORTS, THE DESCRIPTION FOR A DP SAMPLE CODE IS SUBSTRATE DEPLETION, AND THE SUGGESTED ACTION IS TO DILUTE THE SAMPLE AND REPEAT THE TEST. THE HIGHER THAN EXPECTED VITROS CREA RESULTS WERE OBTAINED FROM 2X, 3X, 4X, 6X, OR 10X DILUTIONS OF THE SAMPLES. THE CUSTOMER INFORMED THE ORTHO TSC THAT IT IS UNKNOWN IF AFFECTED PATIENTS TAKE CREATINE SUPPLEMENTS, THEREFORE, INTERFERENCE WITH A SUBSTANCE SUCH AS CREATINE COULD NOT BE CONFIRMED. HISTORICAL QUALITY CONTROL (QC) RESULTS WERE ACCEPTABLE, INDICATING VITROS CREA SLIDE LOT 1545-3576-3187 DID NOT LIKELY CONTRIBUTE TO THE EVENT. VITROS PERFORMANCE VERIFIER (PV) FLUIDS WERE ALSO ACCEPTABLE ON BOTH SYSTEMS, FURTHER VERIFYING ACCEPTABLE PERFORMANCE OF VITROS CREA SLIDE LOT 1520-3567-8487. ADDITIONALLY, CONTINUAL TRACKING AND TRENDING OF COMPLAINTS HAS NOT IDENTIFIED ANY SIGNALS THAT WOULD POINT TO A POTENTIAL SYSTEMIC ISSUE WITH VITROS CREA SLIDE LOT 1520-3567-8487. AN INSTRUMENT ISSUE IS AN UNLIKELY CONTRIBUTOR TO THE EVENT AS DIAGNOSTIC PRECISION TESTING AROUND THE TIME OF THE EVENT INDICATES ACCEPTABLE PERFORMANCE OF THE VITROS 5600 INTEGRATED SYSTEMS. PRE-ANALYTICAL SAMPLE PROCESSING IS NOT A LIKELY CONTRIBUTING FACTOR TO THE EVENT AS THE HIGHER THAN EXPECTED VITROS CREA RESULTS WERE ISOLATED TO ONLY THE AFFECTED PATIENT SAMPLES. A PATIENT CORRELATION USING NON-DILUTED PATIENT SAMPLES YIELDED VITROS CREA RESULTS WITHIN EXPECTATIONS.

    Description of Event or Problem · 0

    A CUSTOMER CONTACTED THE ORTHO CLINICAL DIAGNOSTICS (ORTHO) TECHNICAL SOLUTION CENTER (TSC) TO REPORT HIGHER THAN EXPECTED VITROS CREATININE (CREA) RESULTS WERE OBTAINED FROM MULTIPLE PATIENT SAMPLES WHEN TESTED ON TWO VITROS 5600 INTEGRATED SYSTEMS. THE RESULTS WERE HIGHER THAN EXPECTED WHEN COMPARED TO RESULTS OBTAINED FROM PROCESSING THE SAME PATIENT SAMPLES ON AN ALTERNATE (ROCHE) METHOD. VITROS 56004614 (J1): PATIENT 3 RESULT OF 1.90 MG/DL VS THE EXPECTED RESULT OF 1.15 MG/DL PATIENT 5 RESULT OF 1.70 MG/DL VS THE EXPECTED RESULT OF 1.13 MG/DL PATIENT 6 RESULT OF 1.70 MG/DL VS THE EXPECTED RESULT OF 1.25 MG/DL PATIENT 2 (SAMPLE 2) RESULT OF 1.57 MG/DL VS ROCHE 0.99 VITROS 56004676 (J2): PATIENT 1 RESULT OF 1.60 AND 2.20 MG/DL MG/DL VS THE EXPECTED RESULT OF 1.21 MG/DL PATIENT 2 (SAMPLE 1) RESULT OF 2.40 MG/DL VS THE EXPECTED RESULT OF 0.85 MG/DL BIASED RESULTS OF THE MAGNITUDE AND DIRECTION OBSERVED MAY LEAD TO INAPPROPRIATE PHYSICIAN ACTION IF THEY WERE TO OCCUR UNDETECTED. THE HIGHER-THAN-EXPECTED VITROS CREA RESULTS WERE REPORTED OUTSIDE OF THE LABORATORY. HOWEVER, CORRECTED REPORTS WERE LATER ISSUED. IT REMAINS UNKNOWN IF TREATMENT WAS STARTED, STOPPED, OR ALTERED IN ANY WAY DUE TO THESE RELEASED RESULTS. THERE HAS BEEN NO ALLEGATION OF PATIENT HARM AS A RESULT OF THE EVENT. THIS REPORT IS NUMBER TWO OF FIVE MDRS FOR THIS EVENT. FIVE 3500A FORMS ARE BEING SUBMITTED FOR THIS EVENT AS FIVE DEVICES WERE INVOLVED. THIS REPORT CORRESPONDS TO ORTHO CLINICAL DIAGNOSTICS INC (ORTHO) COMPLAINT NUMBERS (B)(4) AND REPORTABILITY ASSESSMENT (B)(4).

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    24365 VITROS CHEMISTRY PRODUCTS CREA SLIDES IN-VITRO DIAGNOSTICS JFY ORTHO-CLINICAL DIAGNOSTICS, INC. 1520-3567-8487 10758750002849

    Patients

    Seq Age Sex Outcome Treatment
    1 NA Unknown